| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0008 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.002 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |